19 (2.7-5%), and pneumonia (3.4%).**Dose Modifications and Discontinuations Due to ARs:**Dose reductions in 3.6-10%, treatment interruption in 42-51%, and permanent discontinuation of Jaypirca in 9-17% of patients. Permanent discontinuation in >>1% of patients included second primary malignancy, pneumonia, COVID- 19, neutropenia, sepsis,anemia, and cardiac arrythmias.**Most common ARs and Select Laboratory Abnormalities (20%) (all Grades %, Grade 3-4 %)--in a randomized controlled trial:**neutrophil count d ...